D.L. Dumitrașcu *, T. Stavariu *
* D.L. Dumitrașcu, T. Stavariu – Clinica Medicală III, U.M.F. “Iuliu Hatieganu” Cluj
Abstract
The functional gastrointestinal disorders are chronic pathological conditions with disabling potential. A modern mean for the estimation of the impact of these disorders on the patients’s status is the quality of life. There are several questionnaires for the assessement of the quality of life, related to subjective and objective factors. The influence of some drugs on the quality of life represents an index of their therapeutic value. The opiate receptors agonists, among which the most largely used is trimebutine (Debridat) is a drug of choice for the functional gastrointestinal disorders. Preliminary data from a placebo controlled study show the signifcant effect of trimebutine on all parameters which determine the quality of life. This improvement was associated with the improvement of the symptom score for 7 gastrointestinal symptoms. In conclusion, trimebutine improves the quality of life in patients with functional digestive disorders by improving the clinical complaints.